Functional service provider (FSP) models have been a mainstay of clinical development outsourcing for more than 25 years. However, as research and development spending continues to grow, large and mid-sized companies are decreasing their dependence on full-service offerings in favor of FSP firms, and biotech companies are following suit. Achieving the full benefits of an FSP program requires staff augmentation complemented by the right model, appropriate oversight, and a flexible, globally sourced workforce aligned to evolving business needs. For sponsors in this space, understanding how to balance governance, technology, and resource strategy is essential to driving efficiency and accelerating timelines.
Read the full article to learn about:
- How FSP models have grown beyond staff augmentation into hybrid, client- and CRO-managed approaches, and why companies are shifting away from full-service offerings
- The oversight and governance challenges organizations face when transitioning to FSP, including the cost implications of excessive oversight and how to strike the right balance
- Technology’s in enhancing transparency and enabling dynamic resource management, so sponsors can scale teams in alignment with workload demands
- The advantages of a globally sourced workforce and flexible FSP structures for small biotech companies, and how collaborative, partnership-driven research practices are redefining traditional clinical development
